Man Group plc Makes New Investment in LifeStance Health Group, Inc. $LFST

Man Group plc acquired a new position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) in the second quarter, HoldingsChannel reports. The institutional investor acquired 110,155 shares of the company’s stock, valued at approximately $1,180,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC increased its stake in shares of LifeStance Health Group by 19,952.6% during the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares during the period. KBC Group NV bought a new stake in LifeStance Health Group in the 1st quarter valued at $29,000. EverSource Wealth Advisors LLC grew its holdings in LifeStance Health Group by 359.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after buying an additional 5,404 shares in the last quarter. Bayesian Capital Management LP acquired a new position in LifeStance Health Group in the 2nd quarter valued at $52,000. Finally, PNC Financial Services Group Inc. increased its position in LifeStance Health Group by 615.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after buying an additional 7,987 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

Insider Activity at LifeStance Health Group

In other news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the transaction, the insider owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. This represents a 12.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the sale, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. The trade was a 62.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 14,629,850 shares of company stock worth $154,952,012 over the last quarter. 3.50% of the stock is currently owned by insiders.

LifeStance Health Group Stock Performance

Shares of LifeStance Health Group stock opened at $12.89 on Thursday. The business has a 50-day moving average price of $11.38 and a two-hundred day moving average price of $8.73. LifeStance Health Group, Inc. has a 1-year low of $4.77 and a 1-year high of $13.15. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The company has a market cap of $5.00 billion, a P/E ratio of 99.16 and a beta of 1.22.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. During the same quarter in the prior year, the company earned ($0.01) EPS. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. As a group, analysts anticipate that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Canaccord Genuity Group increased their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. The Goldman Sachs Group began coverage on shares of LifeStance Health Group in a research report on Friday, June 5th. They issued a “neutral” rating and a $9.00 price target for the company. Finally, Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.38.

LifeStance Health Group Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.